Tearsheet

Beta Bionics (BBNX)

Market Price (12/4/2025): $30.41 | Market Cap: $1.3 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Beta Bionics (BBNX)

Market Price (12/4/2025): $30.41
Market Cap: $1.3 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -69 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -77%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 67%	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -64%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -68%
2	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Remote Patient Monitoring, Show more.	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 82%
3		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 67%
2	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Remote Patient Monitoring, Show more.
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -69 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -77%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -64%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -68%
5	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 82%
6	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

Valuation, Metrics & Events

	12/4/25	2024	2023	2022
Share Price CYE	$30.41
Market Cap CYE ($ Bil)	1.3	-	-	-
Total Debt ($ Bil)	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.2	0.1	0.1	0.0
Enterprise Value ($ Bil)	1.1
Valuation Ratios
P/S TTM	9.8	0.0	0.0	0.0
P/EBIT TTM	-13.5	0.0	0.0	0.0
P/E TTM	-11.1	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	2.3	1.9	2.2	3.8
P/EBIT TTM (Sector)	299.4	16.8	17.3	15.6
P/E TTM (Sector)	-69.7	95.4	21.3	23.7

	12/4/25	2024	2023
Share Price CYE	$30.41
Market Cap CYE ($ Bil)	1.3	-	-
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.2	0.1	0.1
Enterprise Value ($ Bil)	1.1
Valuation Ratios
P/S TTM	9.8	0.0	0.0
P/EBIT TTM	-13.5	0.0	0.0
P/E TTM	-11.1	0.0	0.0
Sector Ratios
P/S TTM (Sector)	2.3	1.9	2.2
P/EBIT TTM (Sector)	299.4	16.8	17.3
P/E TTM (Sector)	-69.7	95.4	21.3

	BBNX	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.1
Rev Chg Q	63.1%	7.1%
Rev Chg LTM	67.0%	6.1%
Rev Chg 3Y Avg	67.0%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-77.4%	18.8%
CFO/Rev LTM	-63.9%	20.5%
Net Inc Mgn	-87.9%	13.1%
VALUATION	VERY HIGH
P/S	9.8	3.2
P/CFO	-15.3	15.8
P/FCF	-14.3	20.5
P/E	-11.1	23.5
STABILITY	VERY GOOD
Debt/Equity	0.01	0.20
Cash/Assets	0.69	0.07

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Installed customer base	29419	9302025	Link
New patient starts (quarterly)	5334	9302025	Link
Percentage of new patient starts from multiple daily injections (MDI)	70%	9302025	Link
Percentage of new patient starts reimbursed through the PBP channel	Low 30s percentage	9302025	Link
Number of Full-Time Employees	291	1302025	Link

Upcoming
3/24/2026	Earnings Release	Rev: - EPS: -

BBNX Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

For the period leading up to December 4, 2025, Beta Bionics (BBNX) stock experienced significant movement, largely attributable to strong financial performance, increased future projections, and advancements in its product offerings. 1. Strong Third Quarter 2025 Financial Results: Beta Bionics reported robust financial performance for the third quarter of 2025, with net sales reaching $27.3 million. This marked a substantial 63% increase compared to the third quarter of 2024. 2. Raised Full-Year 2025 Revenue Guidance: Following its strong Q3 performance, the company raised its full-year 2025 revenue guidance to exceed $96.5 million, an increase from its previous projection of $88 million to $93 million.

Stock Movement Drivers

Fundamental Drivers

The 54.5% change in BBNX stock from 9/3/2025 to 12/3/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	9032025	12032025	Change
Stock Price ($)	19.68	30.40	54.47%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	�	88.57	�
P/S Multiple	�	14.98	�
Shares Outstanding (Mil)	42.86	43.63	-1.81%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

9/3/2025 to 12/3/2025

	Return	Correlation
BBNX	54.5%
Market (SPY)	6.2%	31.0%
Sector (XLV)	13.3%	16.6%

Fundamental Drivers

The 56.3% change in BBNX stock from 6/4/2025 to 12/3/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	6042025	12032025	Change
Stock Price ($)	19.45	30.40	56.30%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	�	88.57	�
P/S Multiple	�	14.98	�
Shares Outstanding (Mil)	30.50	43.63	-43.08%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

6/4/2025 to 12/3/2025

	Return	Correlation
BBNX	56.3%
Market (SPY)	15.1%	20.8%
Sector (XLV)	16.9%	13.3%

Fundamental Drivers

null
null

Market Drivers

12/3/2024 to 12/3/2025

	Return	Correlation
BBNX
Market (SPY)	14.3%	44.6%
Sector (XLV)	7.0%	35.4%

Fundamental Drivers

null
null

Market Drivers

12/4/2023 to 12/3/2025

	Return	Correlation
BBNX
Market (SPY)	53.2%	44.6%
Sector (XLV)	20.8%	35.4%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BBNX Return	-	-	-	-	-	-
Peers Return	42%	3%	-9%	-5%	-14%	33%	43%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	112%
Monthly Win Rates [3]
BBNX Win Rate	-	-	-	-	-	56%
Peers Win Rate	40%	33%	32%	28%	25%	53%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
BBNX Max Drawdown	-	-	-	-	-	-
Peers Max Drawdown	-25%	-12%	-25%	-25%	-21%	-10%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: A, ATEC, CERS, BLLN, BNBX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)

How Low Can It Go

BBNX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique Key	Event	XLV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-16.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	19.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	599 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-28.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	40.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	116 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-15.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	18.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	326 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-40.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	68.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1100 days	1480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Beta Bionics (BBNX)

We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. We believe this marks a significant advancement over other insulin delivery technologies by offering a differentiated combination of improved glycemic control and a vastly simplified experience for users and caregivers. The iLet was specifically designed to provide improvements in glycemic control relative to currently available treatment options, such as insulin pumps, including partially automated insulin delivery (AID) systems (also known as hybrid closed-loop systems), and multiple daily injections (MDI), while also reducing the complexity and burden of achieving these improved results for PWD. It is enabled by adaptive closed-loop algorithms that continuously learn each person’s unique and ever-changing insulin requirements and then autonomously delivers the correct insulin doses every five minutes throughout the day and night. Only the user’s body weight is required for device initialization and the autonomous determination of all insulin doses, unlike insulin pumps and hybrid closed-loop systems, which require a complex host of parameters to configure. The adaptive closed-loop algorithms are designed to remove the need to manually adjust insulin pump therapy settings and variables required by conventional pump therapy and hybrid closed-loop systems, which both require the user to determine the size and timing of both meal and correction insulin doses and to adjust basal insulin dosing. Therefore, we believe the adaptive closed-loop algorithms can make the iLet easier to initiate and use on a daily basis than other available AID systems. We believe that the iLet represents one of the first significant advances in insulin delivery technology since the commercial availability of hybrid closed-loop systems began in 2017, and that its convenient product features, coupled with improved glycemic control, will appeal to broad segments of PWD who are seeking a simple path to improved disease management. Our initial commercialization efforts for the iLet are in type 1 diabetes (T1D), an indication for which we received FDA clearance in patients six and older in May 2023 in the United States. T1D is an autoimmune disorder that often develops during childhood or adolescence, but can occur at any age, and arises from a person’s immune system attacking and destroying the insulin-producing beta cells in the pancreas. According to the Centers for Disease Control and Prevention (CDC), there are approximately 1.8 million people with T1D currently in the United States, all of whom require daily insulin replacement to manage their disease. The average hemoglobin A1C (HbA1c), a measure of average blood-glucose (BG) levels over an extended period of time, among adults in the United States with T1D is 8.2%, and currently only about 20% of adults with T1D meet or exceed the American Diabetes Association (ADA) goal for HbA1c, which is 7.0% or lower. The remaining 80%, therefore, are at elevated risk of developing an array of potentially life-threatening complications that arise as a result of chronic exposure to hyperglycemia. We believe that one of the principal causes of these suboptimal outcomes is that the complexity of the user experience with most currently available insulin pumps and hybrid closed-loop systems has kept the majority of PWD from adopting them despite the improved disease management they can offer. These systems require PWD to set and to periodically adjust several insulin pump parameters, to quantify daily carbohydrate intake and to frequently calculate proper doses of insulin for their pump to deliver. We believe this complexity, and the constant engagement that is required in order to enjoy the full therapeutic benefits that these systems can offer, limits their uptake to a subset of PWD and to subspecialty healthcare providers (HCPs). We believe that approximately one-third of people with T1D in the United States utilize insulin pumps or hybrid closed-loop systems to receive their daily insulin, while the majority receive their daily insulin via MDI therapy, which is less complex, but often less effective and has been shown to be associated with higher HbA1c levels. This is based on our internal estimates factoring epidemiologic data from government and leading industry organizations such as the CDC, as well as industry sales data from public filings and disclosures made by the leading device manufacturers (Medtronic plc (Medtronic), Tandem Diabetes Care, Inc. (Tandem) and Insulet Corporation (Insulet), who collectively hold approximately 96% market share) and aggregated by third-party data service providers. Our initial commercial results suggest that the iLet’s value proposition is resonating strongly within the MDI population, as approximately 67% of the iLet’s adoption as of September 30, 2024 has come from PWD who were previously utilizing MDI. We were originally incorporated under the laws of the Commonwealth of Massachusetts in October 2015. In August 2024, we reincorporated under the laws of the State of Delaware. Our principal executive offices are located at 11 Hughes, Irvine, California.

AI Generated Analysis | Feedback

1. Imagine Nest (the smart thermostat company) for managing blood sugar levels in people with diabetes – an autonomous system that simplifies a complex daily task.

2. It's like Tesla's Full Self-Driving, but instead of navigating roads, it autonomously navigates a person's blood sugar levels for diabetes management.

3. Think of it as an intelligent personal assistant, like Amazon Alexa or Google Assistant, specifically designed to automate and simplify the complex daily management of diabetes.

AI Generated Analysis | Feedback

iLet Bionic Pancreas System: An automated insulin delivery system designed to autonomously deliver insulin to manage blood glucose levels for people with type 1 diabetes.

AI Generated Analysis | Feedback

Beta Bionics (BBNX) develops and commercializes the iLet Bionic Pancreas System, a prescription-only automated insulin delivery system. While the company utilizes durable medical equipment (DME) suppliers and specialty pharmacies for distribution, its products are designed for and ultimately used by individual patients. Therefore, Beta Bionics primarily serves the following categories of individual customers:

Individuals with Type 1 Diabetes: This primary customer group consists of patients aged 6 years and older who have Type 1 Diabetes and require continuous, automated insulin delivery to manage their blood glucose levels effectively.
Individuals with Insulin-Requiring Type 2 Diabetes: This category includes patients aged 6 years and older who have Type 2 Diabetes and whose condition necessitates insulin therapy, benefiting from the automated insulin delivery capabilities of the iLet system.

AI Generated Analysis | Feedback

The major suppliers of Beta Bionics (BBNX) are:

Flex Ltd. (FLEX)
DexCom, Inc. (DXCM)

AI Generated Analysis | Feedback

Sean Saint, President, CEO & Board Member

Sean Saint is an engineer, entrepreneur, and diabetes technologist who also lives with type 1 diabetes. He founded Companion Medical, where he led the development and launch of the InPen system, the first FDA-cleared smart pen. Companion Medical was acquired by Medtronic in 2020. Before founding Companion Medical, Mr. Saint was an early employee at Dexcom and Tandem Diabetes Care. He also led the collaboration at Tandem Diabetes over 10 years ago to build the first wearable version of the bionic pancreas on a mobile device platform. He holds a Bachelor of Science degree in Mechanical Engineering from California Polytechnic State University – San Luis Obispo and is credited with over 175 issued and pending patent applications.

Stephen Feider, Chief Financial Officer, Treasurer & Secretary

Stephen Feider has extensive finance experience, primarily in healthcare-related companies. He joined Beta Bionics as Chief Financial Officer in August 2022. Prior to Beta Bionics, he served as Finance Director, Diabetes at Medtronic from September 2020 to August 2022. Before Medtronic, he was the Vice President of Finance at Companion Medical from April 2019 to September 2020; Companion Medical was acquired by Medtronic in 2020. Mr. Feider's background also includes serving as Corporate Controller at OurHealth (Marathon Health LLC) and working as a CPA at PwC. He earned both Bachelor's and Master's degrees in Accountancy from Butler University.

Steven Russell, MD, PhD, Chief Medical Officer

Dr. Steven Russell is an endocrinologist and diabetologist with almost 20 years of experience in diabetes management. He serves as an Associate Professor of Medicine at Harvard Medical School and an attending physician at Massachusetts General Hospital (MGH) Diabetes Associates. His research focuses on the application of new technologies to improve diabetes care. He was the principal clinical investigator in a collaboration with Boston University investigators to develop a wearable automated glucose control system, which is now licensed to Beta Bionics. Dr. Russell has directed approximately 20 bionic pancreas clinical trials, including inpatient and home-use studies. He received his PhD in biological chemistry and MD from the University of Texas Southwestern Medical Center.

Mark Hopman, R.Ph, MBA, Chief Commercial Officer

Mark Hopman serves as the Chief Commercial Officer for Beta Bionics. He holds both R.Ph. and MBA credentials.

Mike Mensinger, Chief Product Officer

Mike Mensinger is the Chief Product Officer at Beta Bionics.

AI Generated Analysis | Feedback

Large medical device competitors (e.g., Medtronic, Tandem Diabetes Care, Insulet) are continuously developing and improving their automated insulin delivery (AID) systems. Beta Bionics' iLet Bionic Pancreas differentiates itself through its unique simplicity, significantly reducing or eliminating the need for carb counting. A clear emerging threat is the potential for one of these well-capitalized competitors to launch a next-generation AID system that successfully integrates similar or superior ease-of-use (e.g., advanced algorithms that further simplify meal bolusing and reduce user input) while potentially offering additional advantages such as enhanced glycemic control, smaller device form factors, or broader integration with other digital health platforms. Such a development could directly diminish the iLet's core competitive advantage and market appeal.

AI Generated Analysis | Feedback

Beta Bionics (BBNX), a medical device company, primarily focuses on solutions to enhance the health and quality of life for individuals requiring insulin for diabetes. Their main product is the iLet Bionic Pancreas, an automated insulin delivery system specifically cleared for the treatment of Type 1 Diabetes (T1D) in adults and children aged six years and older. The company is also in the early stages of developing a patch pump and a bihormonal iLet, which would expand its reach to insulin-dependent Type 2 diabetes patients.

Addressable Markets:

Type 1 Diabetes (T1D) Market:
- The global Type 1 Diabetes market size was valued at approximately USD 34.87 billion in 2024 and is projected to reach around USD 74.03 billion by 2034.
- The U.S. Type 1 Diabetes market size alone accounted for about USD 11.23 billion in 2024 and is anticipated to grow to approximately USD 24.27 billion by 2034.
- Across the seven major markets (7MM: US, EU4, UK, and Japan), the T1D market is expected to reach USD 9.9 billion by 2033, up from USD 2.2 billion in 2023. The U.S. market is projected to constitute the largest share, reaching USD 9.0 billion by 2033 within the 7MM.
Automated Insulin Delivery (AID) Devices / Artificial Pancreas Device System Market:
- The global automated insulin delivery devices market size was valued at USD 3.29 billion in 2024 and is projected to reach USD 7.83 billion by 2032.
- The global artificial pancreas device system market size stands at USD 1.01 billion in 2025 and is forecast to reach USD 6.69 billion by 2030.
- Another report estimates the automated insulin delivery system market to expand from USD 901.04 million in 2024 to USD 1.94 billion by 2032.
- North America is expected to be a dominant region in the automated insulin delivery systems industry.

AI Generated Analysis | Feedback

Expected Drivers of Future Revenue Growth for Beta Bionics (BBNX)

Beta Bionics (BBNX) is positioned for future revenue growth over the next 2-3 years, driven by several key factors related to its flagship iLet Bionic Pancreas system and its innovation pipeline. Here are the expected drivers:

Continued Growth in iLet Bionic Pancreas Adoption and New Patient Starts: The iLet Bionic Pancreas is Beta Bionics' primary product, and its increasing adoption is a significant revenue driver. The company has reported substantial year-over-year growth in new patient starts and its installed customer base, indicating strong market penetration and demand for its automated insulin delivery system. This growth is anticipated to continue as the iLet system simplifies diabetes management for individuals with type 1 diabetes.
Expansion of the Pharmacy Benefit Plan (PBP) Channel: The expansion of the Pharmacy Benefit Plan (PBP) channel is crucial for increasing access and affordability of the iLet system. This channel significantly reduces the upfront cost of the pump for both patients and health plans, while also easing administrative burdens for physicians. Beta Bionics has been actively expanding its formulary agreements with major Pharmacy Benefit Managers (PBMs) and has consistently raised its guidance for new patient starts through this high-margin recurring revenue channel.
Innovation Pipeline with New Product Launches (Patch Pump, Bihormonal iLet): Beta Bionics' pipeline of innovative products is expected to drive future revenue growth. The company is actively developing the "Mint" Patch Pump, designed for direct skin adherence without tubing, and the Bihormonal iLet system, which aims to further enhance diabetes management. These next-generation devices are poised to disrupt the market and reinforce Beta Bionics' competitive edge, with ongoing trials for the bihormonal system.
Geographic and Market Expansion: The company is focused on expanding its market reach, not only by penetrating new practices but also by potentially expanding into new patient populations, such as the Type 2 diabetes market. Beta Bionics' strategic hiring in sales supports this growth, indicating an ongoing effort to broaden its customer base and penetrate new sales territories.
System Enhancements and Integrations: Ongoing software updates and integrations for the iLet Bionic Pancreas enhance its appeal and functionality. Recent examples include software updates that improve the cartridge change process and reduce redundant glucose alerts, as well as integration with other continuous glucose monitoring (CGM) systems like the FreeStyle Libre 3 Plus. These enhancements contribute to a better user experience and can attract new customers to the iLet platform.

AI Generated Analysis | Feedback

Share Issuance

Beta Bionics completed an Initial Public Offering (IPO) in January 2025, raising approximately $212.1 million in gross proceeds.
A concurrent private placement alongside the IPO generated an additional $17.0 million in gross proceeds from an existing investor.

Inbound Investments

An existing investor, potentially Wellington Management, participated in a private placement contributing approximately $17.0 million in conjunction with the company's IPO in January 2025.

Outbound Investments

Beta Bionics has strategically partnered with Xeris Pharmaceuticals, Inc. to develop a pump-compatible glucagon formulation.
The company also collaborates with Abbott Diabetes Care Inc. to develop an advanced automated insulin delivery system.

Capital Expenditures

Capital expenditures for the last 12 months amounted to -$3.96 million.
The primary focus of capital and development efforts is on advancing its product pipeline, including a patch pump and a bihormonal iLet.

Better Bets than Beta Bionics (BBNX)

	BBNX	Better Performance than BBNX
Metric	Value	INDUSTRY: Life Sciences Tools & Services
Rev Chg LTM	67.0%	IMDX (316.1%), DCTH (251.5%), SSII (158.4%), STIM (78.6%), PRE (70.1%)
Op Mgn LTM	-77.4%	A (21.3%), DHR (19.0%), TMO (18.4%), IQV (14.2%), NTRA (-16.6%)
CFO/Rev LTM	-63.9%	DHR (26.0%), A (22.0%), IQV (17.6%), TMO (17.5%), NTRA (9.2%)
FCF/Rev LTM	-68.3%	DHR (20.7%), A (16.0%), TMO (14.0%), IQV (13.9%), NTRA (4.4%)
Total Yield	-9.0%	A (4.5%), IQV (4.0%), TMO (3.6%), DHR (2.5%), NTRA (-1.4%)
P/S	9.8	IQV (2.0), TMO (4.2), A (4.9), DHR (5.8), MTD (6.4)
P/Op Inc	-12.6

	BBNX	Better Performance than BBNX
Metric	Value	SECTOR: Health Care
Rev Chg LTM	67.0%	ARWR (2816.2%), CYTK (2609.3%), MDGL (864.2%), HIMS (78.0%), TEM (72.6%)
Op Mgn LTM	-77.4%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%)
CFO/Rev LTM	-63.9%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), LLY (20.5%), UNH (4.8%)
FCF/Rev LTM	-68.3%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), UNH (4.0%), LLY (-0.1%)
Total Yield	-9.0%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/S	9.8	UNH (0.7), MRK (3.3), TMO (4.2), JNJ (4.8), ABBV (6.9)
P/Op Inc	-12.6

	BBNX	Better Performance than BBNX
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	67.0%	CRDO (175.8%), APP (86.4%), HOOD (74.6%), NVDA (71.6%), RDDT (69.7%)
Op Mgn LTM	-77.4%	NVDA (58.1%), MSFT (46.3%), GOOGL (32.2%), AAPL (31.9%), AMZN (11.4%)
CFO/Rev LTM	-63.9%	MSFT (50.0%), NVDA (46.6%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	-68.3%	NVDA (43.6%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-9.0%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.3%)
P/S	9.8	BRK-B (2.7), AMZN (3.5), GOOGL (7.6), AAPL (9.3), META (9.8)
P/Op Inc	-12.6

		Best Bets In Health Care Sector
	BBNX
What You Pay
P/E	-11.1
P/EBIT	-13.5
What You Get
Rev Chg Q	63.1%
Rev Chg LTM	67.0%
Rev Chg 3Y Avg	�
FCF/Rev 3Y Avg	�

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	With Beta Bionics Stock Sliding, Have You Assessed The Risk?	Return
2	Beta Bionics (BBNX) Operating Cash Flow Comparison	Financials
3	Beta Bionics (BBNX) Net Income Comparison	Financials
4	Beta Bionics (BBNX) Operating Income Comparison	Financials
5	Beta Bionics (BBNX) Revenue Comparison	Financials

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to BBNX. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	4.1%	4.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-9.8%	-9.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.0%	6.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.7%	9.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	6.2%	6.2%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	4.1%	4.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-9.8%	-9.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.0%	6.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.7%	9.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	6.2%	6.2%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.3	223.6%	367.4%
COGT	Cogent Biosciences	5.4	152.6%	402.1%
CDTX	Cidara Therapeutics	5.9	115.1%	722.1%
IRWD	Ironwood Pharmaceuticals	0.6	100.5%	-15.8%
TERN	Terns Pharmaceuticals	2.5	95.9%	396.2%
FRGE	Forge Global	0.6	90.3%	217.8%
SGML	Sigma Lithium	1.1	87.3%	-10.6%
INSP	Inspire Medical Systems	4.0	82.8%	-27.3%
NPCE	NeuroPace	0.6	77.2%	48.9%
ALMS	Alumis	0.6	71.9%	-0.3%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
UP	Wheels Up Experience	0.4	-52.7%	-62.4%
CCOI	Cogent Communications	0.9	-51.9%	-72.9%
SMR	NuScale Power	3.0	-50.7%	12.3%
FRMI	Fermi	10.3	-47.5%
AMSC	American Superconductor	1.4	-47.2%	30.1%
TLRY	Tilray Brands	7.5	-46.1%	-46.9%
BTDR	Bitdeer Technologies	2.4	-44.8%	-41.8%
EXOD	Exodus Movement	0.4	-43.1%	-53.3%
STUB	Stubhub	3.5	-39.8%
METC	Ramaco Resources	1.0	-39.4%	66.9%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

Peer Comparisons for Beta Bionics

Peers to compare with:

Financials

	BBNX	A	ATEC	CERS	BLLN	BNBX	Median
Name	Beta Bio.	Agilent .	Alphatec	Cerus	BillionT.	BNB Plus
Mkt Price	30.40	149.26	21.23	1.99	102.76	3.11	25.81
Mkt Cap	1.3	42.4	3.2	0.4	-	-	2.3
Rev LTM	89	6,788	728	199	-	4	199
Op Inc LTM	-69	1,444	-74	-9	-	-13	-13
FCF LTM	-61	1,088	-3	0	-	-14	-3
FCF 3Y Avg	-	1,308	-112	-15	-	-10	-13
CFO LTM	-57	1,495	35	4	-	-13	4
CFO 3Y Avg	-	1,662	-36	-12	-	-10	-11

Growth & Margins

	BBNX	A	ATEC	CERS	BLLN	BNBX	Median
Name	Beta Bio.	Agilent .	Alphatec	Cerus	BillionT.	BNB Plus
Rev Chg LTM	67.0%	4.5%	27.1%	13.0%	-	-51.0%	13.0%
Rev Chg 3Y Avg	-	0.8%	31.8%	8.3%	-	-12.6%	4.6%
Rev Chg Q	63.1%	10.1%	30.4%	14.5%	-	34.3%	30.4%
QoQ Delta Rev Chg LTM	13.5%	2.4%	6.7%	3.5%	-	7.5%	6.7%
Op Mgn LTM	-77.4%	21.3%	-10.1%	-4.8%	-	-306.1%	-10.1%
Op Mgn 3Y Avg	-	21.5%	-21.8%	-11.9%	-	-170.3%	-16.8%
QoQ Delta Op Mgn LTM	2.7%	-0.1%	3.8%	1.3%	-	42.9%	2.7%
CFO/Rev LTM	-63.9%	22.0%	4.8%	1.8%	-	-301.5%	1.8%
CFO/Rev 3Y Avg	-	24.6%	-7.6%	-7.5%	-	-141.9%	-7.6%
FCF/Rev LTM	-68.3%	16.0%	-0.5%	0.1%	-	-313.1%	-0.5%
FCF/Rev 3Y Avg	-	19.4%	-21.7%	-9.7%	-	-147.0%	-15.7%

Valuation

	BBNX	A	ATEC	CERS	BLLN	BNBX	Median
Name	Beta Bio.	Agilent .	Alphatec	Cerus	BillionT.	BNB Plus
Mkt Cap	1.3	42.4	3.2	0.4	-	-	2.3
P/S	9.8	4.9	3.0	1.5	-	-	4.0
P/EBIT	-13.5	22.2	-19.2	-42.1	-	-	-16.4
P/E	-11.1	27.5	-14.2	-19.1	-	-	-12.7
P/CFO	-15.3	22.4	62.8	85.5	-	-	42.6
Total Yield	-9.0%	4.5%	-7.0%	-5.2%	-	-	-6.1%
Dividend Yield	0.0%	0.8%	0.0%	0.0%	-	-	0.0%
FCF Yield 3Y Avg	-	3.7%	-11.2%	-5.1%	-	-	-5.1%
D/E	0.0	0.1	0.3	0.3	-	-	0.2
Net D/E	-0.3	0.1	0.2	0.1	-	-	0.1

Returns

	BBNX	A	ATEC	CERS	BLLN	BNBX	Median
Name	Beta Bio.	Agilent .	Alphatec	Cerus	BillionT.	BNB Plus
1M Rtn	9.7%	3.2%	10.1%	30.9%	-	-8.5%	9.7%
3M Rtn	54.5%	19.4%	33.5%	51.9%	-	-	42.7%
6M Rtn	56.3%	30.4%	72.9%	38.2%	-	-	47.2%
12M Rtn	-	8.0%	112.3%	12.4%	-	-	12.4%
3Y Rtn	-	-2.0%	106.7%	-52.0%	-	-	-2.0%
1M Excs Rtn	9.8%	3.2%	10.1%	31.0%	-	-8.5%	9.8%
3M Excs Rtn	45.9%	11.1%	22.9%	44.3%	-	-	33.6%
6M Excs Rtn	41.6%	15.7%	58.2%	23.5%	-	-	32.5%
12M Excs Rtn	-	-4.5%	89.0%	-6.0%	-	-	-4.5%
3Y Excs Rtn	-	-72.6%	50.7%	-119.0%	-	-	-72.6%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022
Filing Date	10/28/2025	3/25/2025	1/31/2025	1/31/2025
Key Financials
Total Revenue	89	65	12	0
EBITDA	-62	-43	-34	-63
Operating Income	-69	-45	-36	-66
Net Income	-78	-55	-44	-65
EPS	-2.07	-1.28	-1.45	-2.12
Growth Rates
Total Revenue Growth	67.0%	442.9%	6601.1%	-
EBITDA Growth	-57.0%	-27.3%	46.1%	-
Operating Income Growth	-69.0%	-26.2%	45.6%	-
Net Income Growth	-40.3%	-24.2%	31.9%	-
Margins
EBITDA Margin	-69.7%	-66.0%	-281.4%	-35000.0%
Operating Income Margin	-77.4%	-69.5%	-298.9%	-36784.4%
Net Income Margin	-87.9%	-84.1%	-367.6%	-36173.7%
Cash & Debt
Total Cash	229	104	97	28
Total Debt	8	7	4	4
Net Debt / (Cash)	-221	-96	-93	-24
Cash Flows
Net Cash from Operations	-57	-48	-32	-60
Free Cash from Operations	-61	-52	-33	-61
Returns to Shareholders
Dividends	0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023
Filing Date	10/28/2025	7/29/2025	5/6/2025	3/25/2025	1/31/2025	7/29/2025	5/6/2025	1/31/2025
Key Financials Quarterly
Total Revenue	27	23	18	20	17	15	13	8
Ebitda	-16	-19	-18	-8	-9	-11	-9	-10
Operating Income	-17	-20	-19	-13	-11	-12	-9	-8
Net Income	-14	-17	-29	-18	-10	-14	-12	-19
EPS	-0.33	-0.39	-0.93	-0.42	-0.23	-0.34	-0.41	-0.62
Key Financials TTM
Total Revenue TTM	89	78	70	65	53	-	-	-
Ebitda TTM	-62	-54	-46	-37	-39	-	-	-
Operating Income TTM	-69	-63	-54	-45	-41	-	-	-
Net Income TTM	-78	-73	-71	-55	-55	-	-	-
Growth Rates Quarterly
Total Revenue Growth	63.1%	54.4%	36.4%	144.8%	-	-	-	-
EBITDA Growth	-79.4%	-71.5%	-102.9%	19.8%	-	-	-	-
Operating Income Growth	-55.3%	-68.6%	-97.2%	-55.8%	-	-	-	-
Net Income Growth	-45.9%	-16.6%	-130.2%	3.9%	-	-	-	-
Margins Quarterly
EBITDA Margin	-60.0%	-82.7%	-102.3%	-39.5%	-54.6%	-74.5%	-68.7%	-120.6%
Operating Income Margin	-62.5%	-85.5%	-105.7%	-63.8%	-65.7%	-78.3%	-73.1%	-100.2%
Net Income Margin	-52.1%	-72.6%	-162.5%	-88.6%	-58.3%	-96.1%	-96.3%	-225.7%
Cash & Debt
Total Cash	229	250	231	104	61	-	-	97
Total Debt	8	7	7	7	7	0	0	4
Net Debt / (Cash)	-221	-243	-224	-96	-54	-	-	-93
Cash Flows Quarterly
FCF from Operations	-9	-14	-20	-14	-10	-12	-12	-6
Cash Flows TTM
FCF from Operations TTM	-57	-57	-56	-48	-40	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-15.8%	-19.8%	-18.0%	-	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-15.9%	-15.6%	-13.1%	-	-	-	-	-

Price Behavior

Price Behavior

Market Price	$30.40
Market Cap ($ Bil)	1.3
First Trading Date	01/30/2025
Distance from 52W High	-3.5%
	50 Days	200 Days
DMA Price	$27.02	$27.02
DMA Trend	up	up
Distance from DMA	12.5%	12.5%
	3M	1YR
Volatility	76.5%	86.2%
Downside Capture	85.87	185.33
Upside Capture	264.81	188.08
Correlation (SPY)	31.6%

BBNX Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.88	2.01	1.83	1.29	-0.34	-0.17
Up Beta	1.57	2.38	1.54	-0.80	0.44	0.04
Down Beta	3.93	3.66	2.76	2.78	0.19	0.53
Up Capture	309%	334%	319%	230%	242%	27%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	11	25	36	68	108	108
Down Capture	92%	-4%	42%	74%	128%	84%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	8	16	26	56	99	99

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

null

Based On 5-Year Data

null

Based On 10-Year Data

null

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	3,572,312
Short Interest: % Change Since 10312025	-0.9%
Average Daily Volume	576,204
Days-to-Cover Short Interest	6.20
Basic Shares Quantity	43,634,006
Short % of Basic Shares	8.2%

Returns Analyses

	Title
0	With Beta Bionics Stock Sliding, Have You Assessed The Risk?

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	10282025	10-Q 9/30/2025
6302025	7292025	10-Q 6/30/2025
3312025	5062025	10-Q 3/31/2025
12312024	3252025	10-K 12/31/2024
12312023	1312025	424B4 12/31/2023

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Beta Bionics (BBNX)

Market Price (12/4/2025): $30.41 | Market Cap: $1.3 BilSector: Health Care | Industry: Life Sciences Tools & Services

Beta Bionics (BBNX)

Market Price (12/4/2025): $30.41Market Cap: $1.3 BilSector: Health CareIndustry: Life Sciences Tools & Services

Valuation, Metrics & Events

BBNX Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Beta Bionics (BBNX)

Addressable Markets:

Expected Drivers of Future Revenue Growth for Beta Bionics (BBNX)

Interactive Breakdown

Better Bets than Beta Bionics (BBNX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Beta Bionics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/4/2025): $30.41 | Market Cap: $1.3 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (12/4/2025): $30.41
Market Cap: $1.3 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services